FDA approved Zycubo (copper histidinate) on January 12, 2026 for Menkes disease, a rare genetic disorder of copper transport that affects infants, per the agency's list of 2026 novel drug approvals. It is the first approval of the year and gives families a dedicated therapy for a condition long managed with improvised copper injections.
This article publishes information, not medical advice. Treatment decisions for a rare genetic condition belong with a metabolic disorder specialist; ask your center whether this therapy is appropriate and how to access it.
What is Menkes disease?
Menkes disease is an X-linked recessive disorder caused by mutations in the ATP7A gene, which encodes a protein that moves copper across cell membranes. Without working copper transport, infants develop brittle, steely hair, developmental regression, seizures, and connective tissue problems, typically within the first months of life. The condition is rare — usually described as affecting roughly 1 in 100,000 or fewer newborns — which is exactly the profile the FDA's orphan-drug framework exists for.
Related stories: FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run · FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs.
What does copper histidinate do?
Because the genetic defect blocks copper absorption and distribution, the logic of treatment is to bypass the gut and deliver copper bound to histidine, its natural transport partner, directly into the bloodstream. Clinical experience with copper histidinate injections predates this approval, but a formal approval matters practically: it means a manufactured, standardized, FDA-reviewed product with labeling, rather than a compounded preparation arranged case by case.
Why rare disease approvals look different
For conditions this rare, trials enroll dozens of patients, not thousands, and endpoints often focus on survival and neurodevelopment rather than surrogate markers. Early treatment is the recurring theme in Menkes literature: infants treated before symptoms or within weeks of onset fare better, which makes newborn recognition — kinky hair, hypothermia, hypoglycemia in a male infant — the practical first step for families and pediatricians.
What to watch next
Check whether the drug appears on the FDA's 2026 novel approvals list with prescribing and access information, and ask your metabolic center about insurance coverage pathways for orphan drugs — many states' Medicaid programs and large insurers process rare-disease therapies through prior authorization. An earlier diagnosis pathway, including newborn screening discussions for ATP7A mutations in affected families, is the follow-on question worth raising with a genetic counselor.
For more context, read FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run.
For more context, read orzeyful fda approval.
For more context, read utebzi fda approval.